A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03

被引:18
作者
Okabe, Hiroshi [1 ]
Hata, Hiroaki [2 ]
Ueda, Shugo [3 ]
Zaima, Masazumi [4 ]
Tokuka, Atsuo [5 ]
Yoshimura, Tsunehiro [6 ]
Ota, Shuichi [7 ]
Kinjo, Yousuke [1 ]
Yoshimura, Kenichi [8 ]
Sakai, Yoshiharu [1 ]
机构
[1] Kyoto Univ, Dept Surg, Grad Sch Med, Kyoto, Japan
[2] Kyoto Med Ctr, Dept Surg, Kyoto, Japan
[3] Kitano Hosp, Dept Surg Gastroenterol, Osaka, Japan
[4] Shiga Med Ctr Adults, Dept Surg, Shiga, Japan
[5] Shimane Prefectural Cent Hosp, Dept Surg, Shimane, Japan
[6] Tenri Hosp, Dept Abdominal Surg, Nara, Japan
[7] Saiseikai Noe Hosp, Dept Surg, Osaka, Japan
[8] Kanazawa Univ Hosp, Innovat Clin Res Ctr, Ishikawa, Japan
关键词
gastric cancer; neoadjuvant chemotherapy; phase II; clinical stage III; PLUS CISPLATIN; ADJUVANT CHEMOTHERAPY; PERIOPERATIVE CHEMOTHERAPY; PREOPERATIVE CHEMOTHERAPY; D2; GASTRECTOMY; SURGERY; TRIAL; ADENOCARCINOMA; MULTICENTER; GUIDELINES;
D O I
10.1002/jso.24096
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectivesA multi-center phase II study was conducted to evaluate the safety and efficacy of neoadjuvant chemotherapy (NAC) with S-1 plus cisplatin for advanced gastric cancer. MethodsThe eligibility criteria were clinical T3/T4 or N2, not Stage IV. Patients received two 35-day cycles of S-1 plus cisplatin, and then underwent D2 gastrectomy. The primary endpoint was 3-year progression free survival (PFS). Secondary endpoints were ratio of R0 resection, response rate, adverse events, and overall survival. A sample size of 49 was determined to have 80% power for detecting 15% improvement in the 3-year PFS over 55% at a one-sided alpha of 0.1. ResultsAmong 53 patients enrolled, 44 patients completed two cycles of NAC (83%), and 48 patients underwent R0 resection (91%). Postoperative complications occurred in 13 patients (26%). A pathological response was confirmed in 24 patients (45%), including four complete responses. The 3-year PFS was 50.7%, while the 3-year OS was 74.9%. ConclusionsAlthough the observed 3-year PFS rate was worse than expected, NAC with S1 plus cisplatin was safe and led to a high rate of R0 resection. A randomized controlled trial is needed to make conclusions about the effectiveness of NAC in Japanese patients undergoing D2 resection. J. Surg. Oncol. 2016;113:36-41. (c) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:36 / 41
页数:6
相关论文
共 50 条
[41]   A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106) [J].
Keisuke Kurimoto ;
Kiyoshi Ishigure ;
Yoshinari Mochizuki ;
Akiharu Ishiyama ;
Takanori Matsui ;
Seiji Ito ;
Hiroshi Nakayama ;
Nobutake Tanaka ;
Daisuke Kobayashi ;
Junichi Sakamoto ;
Akimasa Nakao ;
Yasuhiro Kodera .
Gastric Cancer, 2015, 18 :354-359
[42]   Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study [J].
Shinkai, Masayuki ;
Imano, Motohiro ;
Chiba, Yasutaka ;
Hiraki, Yoko ;
Kato, Hiroaki ;
Iwama, Mitsuru ;
Shiraisi, Osamu ;
Yasuda, Atsushi ;
Tsubaki, Masahiro ;
Nishida, Shozo ;
Kimura, Yutaka ;
Yasuda, Takushi .
ANTICANCER RESEARCH, 2018, 38 (10) :5969-5974
[43]   Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer [J].
Tsuburaya, Akira ;
Nagata, Naoki ;
Cho, Haruhiko ;
Hirabayashi, Naoki ;
Kobayashi, Michiya ;
Kojima, Hiroshi ;
Munakata, Yasuhiro ;
Fukushima, Ryoji ;
Kameda, Yoichi ;
Shimoda, Tadakazu ;
Oba, Koji ;
Sakamoto, Junichi .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) :1309-1314
[44]   S-1 combined with cisplatin chemotherapy for advanced gastric cancer [J].
Chen Weidong ;
Xia Lijun .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (05) :54-56
[45]   Preoperative Systemic and Intraperitoneal Chemotherapy Consisting of S-1, Cisplatin and Docetaxel in Patients with Marginally Resectable Gastric Cancer [J].
Kurokawa, Yukinori ;
Hamakawa, Takuya ;
Miyazaki, Yasuhiro ;
Takahashi, Tsuyoshi ;
Yamasaki, Makoto ;
Miyata, Hiroshi ;
Nakajima, Kiyokazu ;
Takiguchi, Shuji ;
Mori, Masaki ;
Doki, Yuichiro .
ANTICANCER RESEARCH, 2015, 35 (04) :2223-2228
[46]   Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1 [J].
Watanabe, Hayato ;
Hayashi, Tsutomu ;
Komori, Keisuke ;
Hara, Kentaro ;
Maezawa, Yukio ;
Kano, Kazuki ;
Shimoda, Yota ;
Fujikawa, Hirohito ;
Aoyama, Toru ;
Yamada, Takanobu ;
Yamamoto, Naoto ;
Cho, Haruhiko ;
Ito, Hiroyuki ;
Shiozawa, Manabu ;
Yukawa, Norio ;
Morinaga, Soichiro ;
Yoshikawa, Takaki ;
Rino, Yasushi ;
Masuda, Munetaka ;
Ogata, Takashi ;
Oshima, Takashi .
ANTICANCER RESEARCH, 2020, 40 (03) :1683-1690
[47]   Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer [J].
Kunisaki, Chikara ;
Takahashi, Masazumi ;
Makino, Hirochika ;
Oshima, Takashi ;
Fujii, Shoichi ;
Takagawa, Ryo ;
Kimura, Jun ;
Kosaka, Takashi ;
Ono, Hidetaka A. ;
Akiyama, Hirotoshi ;
Kameda, Kunio ;
Kito, Fumihiko ;
Morita, Satoshi ;
Endo, Itaru .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (06) :1363-1368
[48]   Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer [J].
Tsuchida, Kazuhito ;
Sato, Tsutomu ;
Aoyama, Toru ;
Atsumi, Yosuke ;
Kano, Kazuki ;
Maezawa, Yukio ;
Kazama, Keisuke ;
Numata, Masakatsu ;
Yamada, Takanobu ;
Tamagawa, Hiroshi ;
Murakami, Hitoshi ;
Oshima, Takashi ;
Saeki, Hiroyuki ;
Cho, Haruhiko ;
Yukawa, Norio ;
Yamamoto, Yuji ;
Masuda, Munetaka ;
Rino, Yasushi .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (03) :371-378
[49]   A Comparison of Multimodality Treatment: Two and Four Courses of Neoadjuvant Chemotherapy Using S-1/CDDP or S-1/CDDP/Docetaxel Followed by Surgery and S-1 Adjuvant Chemotherapy for Macroscopically Resectable Serosa-positive Gastric Cancer: A Randomized Phase II Trial (COMPASS-D Trial) [J].
Yoshikawa, Takaki ;
Taguri, Masataka ;
Sakuramoto, Shinichi ;
Kunisaki, Chikara ;
Fukunaga, Tetsu ;
Ito, Seiji ;
Cho, Haruhiko ;
Tanabe, Kazuaki ;
Nishikawa, Kazuhiro ;
Matsui, Takanori ;
Morita, Satoshi ;
Tsuburaya, Akira .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (01) :74-77
[50]   Phase II study of neoadjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer clinical T4 or N2-3 [J].
Serizawa, Akiko ;
Kuramochi, Hidekazu ;
Taniguchi, Kiyoaki ;
Ota, Masaho ;
Katagiri, Satoshi ;
Yamada, Takuji ;
Kotake, Sho ;
Ito, Shunichi ;
Suzuki, Kazuomi ;
Yamamoto, Masakazu .
MEDICAL ONCOLOGY, 2021, 38 (09)